PIK3CA and cancer: PIK3CA mutant selective inhibitors would likely have major advantages in cancer treatment as they can evade feedback mechanisms that counteract pharmacological inhibition of WT PIK3CA. Mutant selective inhibitors have been discovered that lead to selective degradation of E545K and H1047R over WT54, along with recent reports of H1047R selective inhibitors.